<DOC>
	<DOCNO>NCT00417196</DOCNO>
	<brief_summary>This study design evaluate safety , pharmacodynamic pharmacokinetic effect individual escalate intravenous dos QAX576 healthy volunteer .</brief_summary>
	<brief_title>Safety , Pharmacodynamic Pharmacokinetic Effects QAX576 Healthy Volunteers .</brief_title>
	<detailed_description />
	<criteria>Healthy male female subject age 18 45 year , inclusive , good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . Only surgically sterilize female subject procedure perform least 6 month prior screen supportive clinical documentation allow participate study . Male subject must use doublebarrier local contraception , i.e. , spermicidal gel plus condom , entire duration study , Study Completion visit ( i.e. , refrain father child 4 month follow last study drug administration ) . Vital sign within follow range : Oral body temperature 35.037.5Â°C . Supine systolic blood pressure , 90140 mm Hg . Supine diastolic blood pressure , 5090 mm Hg . Supine pulse rate , 5090 beat per minute ( bpm ) . When blood pressure pulse take 3 minute stand , shall 20 mm Hg drop systolic 10 mm Hg drop diastolic blood pressure increase heart rate ( &gt; 20 bpm ) associate clinical manifestation postural hypotension . Body mass index ( BMI ) must within range 18 28 kg/m2 . Subjects must weigh 50 100 kg ( inclusive ) . Smokers ( use tobacco product previous 3 month ) . Smokers report tobacco use urine cotinine great 500 ng/mL . Use prescription drug within 4 week prior dose , overthecounter ( OTC ) medication ( vitamin , herbal supplement , dietary supplement ) within 2 week prior dose . Acetaminophen acceptable clinical documentation . Participation clinical investigation within 4 week prior dose longer required local regulation , limitation participation base local regulation . Donation loss 400 mL blood within 8 week prior first dose , longer required local regulation . Significant illness within 2 week prior dose . A past medical history clinically significant ECG abnormality . History autonomic dysfunction acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease , treat treat ) clinically significant drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis ) . A known hypersensitivity study drug drug similar study drug.. History presence surgical medical condition , opinion investigator , may jeopardize subject case participation study , include hepatic , hematological , immunological , disorders.. History clinical schistosomiasis travel within precede 6 month area endemic schistosomiasis , include limited Southeast Asia Northwest Africa Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>pharmacodynamic effect , safety , healthy subject ,</keyword>
	<keyword>Healthy male female subject</keyword>
</DOC>